Buscar
Mostrando ítems 1-10 de 83
Sorafenib after arterial chemoembolization in child-pugh A and B cirrhotic patients with intermediate hepatocellular carcinoma: a retrospective analysis
(2015)
Introduction: Hepatocellular carcinoma (HCC) is a leading cause of mortality among cirrhotic patients, and current guidelines recommend single-treatment modalities according to patient and liver disease classifications. ...
Insuficiência pancreática exócrina em usuários de sorafenibe para tratamento do carcinoma hepatocelular
(DME - Departamento de Medicina – Aracaju - PresencialUniversidade Federal de Sergipe, 2022)
PIB: A score to select sorafenib treatment candidates for hepatocellular carcinoma in resource-limited settings
(Baqiyatallah Research Center, 2018-10)
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death globally. Sorafenib, a multi-tyrosine kinase inhibitor, remains the standard of care for patients with inoperable or advanced-stage HCC. ...
Effect of Sorafenib on Murine Liver Regeneration
(WILEY-BLACKWELL, 2011-02)
Hepatocellular carcinoma (HCC) is a common cause of cancer-related death. Sorafenib prolongs survival of patients with advanced disease and is approved for the systemic treatment of unresectable HCC. It possesses antiangiogenic ...
Effect of Sorafenib on Murine Liver Regeneration
(WILEY-BLACKWELL, 2011-02)
Hepatocellular carcinoma (HCC) is a common cause of cancer-related death. Sorafenib prolongs survival of patients with advanced disease and is approved for the systemic treatment of unresectable HCC. It possesses antiangiogenic ...
Sorafenib for Treatment of Hepatocellular Carcinoma: A Survival Analysis from the South American Liver Research Network
(Lippincott Williams, 2019-07)
Goals:We aim to describe the efficacy, safety profile, and variables associated with survival in patients with hepatocellular carcinoma (HCC) treated with sorafenib in South America.Background:Sorafenib has been shown to ...
Sirtuin 1 and 2 inhibitors enhance the inhibitory effect of sorafenib in hepatocellular carcinoma cells
(Elsevier Science, 2021-02)
Multidrug resistance (MDR) counteracts the efficiency of sorafenib, an important first-line therapy for hepatocellular carcinoma (HCC). Sirtuins (SIRTs) 1 and 2 are associated with tumor progression and MDR. We treated 2D ...